← All trials
NCT07239674
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2025
- Primary completion
- Nov 30, 2027
- Completion date
- Jun 30, 2028
- First posted
- Nov 20, 2025
- Last posted
- Nov 20, 2025
- Enrollment
- 646
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sichuan UniversityLead sponsor
- Sichuan UniversitySponsor investigator
- Chongqing Medical UniversityCollaborator
- Kunming Medical UniversityCollaborator
- Kunming Medical UniversityCollaborator
- Guizhou Medical UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Zhejiang UniversityCollaborator
- Shanxi Medical UniversityCollaborator
- Inner Mongolia Medical UniversityCollaborator
- Qingdao UniversityCollaborator
- Hacettepe UniversityCollaborator
- Xiamen UniversityCollaborator
- Ningxia Medical UniversityCollaborator
- Sichuan UniversityCollaborator
- Sichuan UniversityCollaborator
- Sichuan UniversityCollaborator
- Air Force Military Medical University, ChinaCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.